Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer

NCT05977036 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT05977036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05977036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer
Lead sponsor
Washington University School of Medicine
Phase
Not applicable
Overall status
Recruiting
Start date
September 25, 2024
Completion date
September 30, 2035
Enrollment
145 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer, unresectable breast cancer